The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Immunosenescence, Metabolism
In brief
The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.
Key facts
- Study ID
- NCT06907329
- Run by
- Qing Su
- People needed
- 126
- Starts
- 2025-06-05
- Expected to finish
- 2027-03-31
- Last updated by the study team
- 2025-07-08
Who can join
Age: 50 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 50-70 years with overweight or obesity (BMI 24kg/m2);
- At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c <7% without glucose-lowering drug therapy;
- Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
You may not qualify if…
- Patients with tumours;
- Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
- Severe cardiovascular disease or cardiac insufficiency;
- Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg;
- Chronic obstructive pulmonary disease;
- Chronic active hepatitis or cirrhosis;
- Chronic renal insufficiency;
- Stroke patients
- Severe haematological diseases;
- Infectious diseases;
- Mental illness;
- Other conditions that, in the opinion of the investigator, may affect the results of the study;
- Those who have used NMN or other anti-aging agents within six months.
- Premenopausal woman
- ALT, AST values are more than three times higher than the upper limit of the normal reference range
Where it is running
- Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.